Literature DB >> 16723992

p21-activated kinases in cancer.

Rakesh Kumar1, Anupama E Gururaj, Christopher J Barnes.   

Abstract

The pivotal role of kinases in signal transduction and cellular regulation has lent them considerable appeal as pharmacological targets across a broad spectrum of cancers. p21-activated kinases (Paks) are serine/threonine kinases that function as downstream nodes for various oncogenic signalling pathways. Paks are well-known regulators of cytoskeletal remodelling and cell motility, but have recently also been shown to promote cell proliferation, regulate apoptosis and accelerate mitotic abnormalities, which results in tumour formation and cell invasiveness. Alterations in Pak expression have been detected in human tumours, which makes them an attractive new therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723992     DOI: 10.1038/nrc1892

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  262 in total

1.  p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Authors:  Michelle K Y Siu; Hoi Yan Chan; Daniel S H Kong; Esther S Y Wong; Oscar G W Wong; Hextan Y S Ngan; Kar Fai Tam; Hongquan Zhang; Zhilun Li; Queeny K Y Chan; Sai Wah Tsao; Staffan Strömblad; Annie N Y Cheung
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-06       Impact factor: 11.205

2.  A FOXO-Pak1 transcriptional pathway controls neuronal polarity.

Authors:  Luis de la Torre-Ubieta; Brice Gaudillière; Yue Yang; Yoshiho Ikeuchi; Tomoko Yamada; Sara DiBacco; Judith Stegmüller; Ulrich Schüller; Dervis A Salih; David Rowitch; Anne Brunet; Azad Bonni
Journal:  Genes Dev       Date:  2010-04-15       Impact factor: 11.361

3.  ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration.

Authors:  Liangping Yuan; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald
Journal:  Clin Exp Metastasis       Date:  2010-06-06       Impact factor: 5.150

4.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Authors:  Amy Baldwin; Dorre A Grueneberg; Karin Hellner; Jacqueline Sawyer; Miranda Grace; Wenliang Li; Ed Harlow; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

Review 5.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

Review 6.  Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.

Authors:  Yang-Guang Shao; Ke Ning; Feng Li
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

7.  p21-activated kinase-1 signaling regulates transcription of tissue factor and tissue factor pathway inhibitor.

Authors:  Beatriz Sánchez-Solana; Mona Motwani; Da-Qiang Li; Jeyanthy Eswaran; Rakesh Kumar
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

8.  PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

Authors:  Arti Verma; Sandeep Artham; Abdulrahman Alwhaibi; Mir S Adil; Brian S Cummings; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-03-30       Impact factor: 5.858

9.  P21 activated kinase-1 (Pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor β expression and enhanced matrix metalloproteinase 9 secretion.

Authors:  Anna Goc; Ahmad Al-Azayzih; Maha Abdalla; Belal Al-Husein; Sravankumar Kavuri; Jeffrey Lee; Kelvin Moses; Payaningal R Somanath
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

10.  RhoJ modulates melanoma invasion by altering actin cytoskeletal dynamics.

Authors:  Hsiang Ho; Amelia Soto Hopkin; Rubina Kapadia; Priya Vasudeva; Jonathan Schilling; Anand K Ganesan
Journal:  Pigment Cell Melanoma Res       Date:  2013-01-07       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.